CJC-1295 vs Ipamorelin: Research Comparison 2026

CJC-1295 vs Ipamorelin: Research Comparison 2026 Compare mechanisms, receptor binding, and published research for CJC-1295 and Ipamorelin GH peptides. CJC-1295 vs Ipamorelin. Compare mechanisms, receptor binding, and published research for CJC-1295 and Ipamorelin GH peptides. Key Takeaways CJC-1295 is a GHRH analog: It binds to GHRH receptors in the pituitary to stimulate growth hormone release Ipamorelin is a GHRP (ghrelin mimetic): It binds to GHS-R1a receptors via a completely different pathway Different mechanisms make them complementary: Published research often examines their combination due to non-competing receptor targets Neither is FDA-approved: Both remain research compounds not intended for human therapeutic use Combination protocols appear in published literature: Studies by Bowers et al. describe amplification effects when GHRH and GHRP pathways are co-activated CJC-1295 and Ipamorelin are frequently discussed together in growth hormone research contexts, but they work through fundamentally different mechanisms — and researchers also ask how this combination compares to synthetic HGH (somatropin) . This comparison examines their molecular structures, receptor targets, and the published research supporting combination study protocols. For reconstitution math and syringe-unit examples, see our how to dose CJC-1295 and Ipamorelin research guide. For the separate HPG-axis question, see our best peptides for testosterone ranking. Researchers comparing GHRH-family compounds often cross-reference approved or clinically advanced analogs to understand what a successful regulatory path looks like. For that context, review our Tesamorelin FDA Approval Status breakdown and our Sermorelin FDA Approval Status guide. If you are comparing research supply formats alongside the literature, see our Ipamorelin product page . Researchers watching checkout price can also apply our CJC-1295 coupon code for 10% off. Why researchers compare them: Both peptides influence growth hormone secretion, but through distinct receptor pathways. Understanding these differences is essential for designing research protocols that aim to study GH release patterns, receptor specificity, or synergistic effects. Molecular Identity Comparison Property CJC-1295 (No DAC) Ipamorelin Full Name Modified Growth Hormone Releasing Hormone 1-29 Ipamorelin acetate Amino Acid Count 29 (with 4 amino acid substitutions) 5 (pentapeptide) Molecular Weight ~3367.9 g/mol ~711.9 g/mol Mechanism Class GHRH analog GHRP (Growth Hormone Releasing Peptide) Primary Receptor GHRH-R (Growth Hormone Releasing Hormone Receptor) GHS-R1a (Ghrelin/Growth Hormone Secretagogue Receptor) Research Half-life ~30 minutes (No DAC) / ~8 days (with DAC) ~2 hours The size difference is significant: CJC-1295 is a 29-amino-acid modified hormone fragment, while Ipamorelin is a compact 5-amino-acid synthetic peptide. This structural difference reflects their distinct evolutionary origins—CJC-1295 derives from natural GHRH, while Ipamorelin was designed de novo as a selective ghrelin receptor agonist. CJC-1295: Mechanism of Action CJC-1295 is a modified analog of the f